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Abstract
Background: High dose oral thiamine may have a role in treating diabetes, heart failure, and hypermetabolic
states. The purpose of this study was to determine the pharmacokinetic profile of oral thiamine hydrochloride at
100 mg, 500 mg and 1500 mg doses in healthy subjects.
Methods: This was a randomized, double-blind, single-dose, 4-way crossover study. Pharmacokinetic measures
were calculated.
Results: The AUC0-10 hr and Cmax values increased nonlinearly between100 mg and 1500 mg. The slope of the
AUC0-10 hr vs dose, as well as the Cmax vs dose, plots are steepest at the lowest thiamine doses.
Conclusion: Our study demonstrates that high blood levels of thiamine can be achieved rapidly with oral thiamine
hydrochloride. Thiamine is absorbed by both an active and nonsaturable passive process.
Trial Registration: ClinicalTrials.gov: NCT00981877
Background
Thiamine, vitamin B1, was isolated in 1926 and synthe-
sized in 1936. Its importance for preventing illness was
known as early as the turn of the century. Thiamine
requirements are related to energy metabolism; specifi-
cally, 0.33 mg of thiamine are required for every 4400 kJ
of energy. For adults the DRI of thiamine is between 1.1
and 1.4 mg per day. The primary active form of the vita-
min, thiamine diphosphate (ThDP), is also known as
thiamine pyrophosphate (TPP). ThDP is a necessary
cofactor for enzymes related to carbohydrate metabo-
lism: pyruvate dehydrogenase (PDH), a-ketoglutarate
dehydrogenase, and transketolase.
Thiamine, vitamin B1, is not synthesized by humans
and is not stored in large quantities in humans [1]. One
of its phosphorylated forms, thiamine diphosphate, also
known as thiamine pyrophosphate, is the primary active
form of the vitamin. Thiamine diphosphate is a neces-
sary co-factor for several enzymes involved in the glyco-
lytic pathway, citric acid cycle, pentose phosphate
pathway, and degradation of branched chain amino
acids.
Thiamine is used to treat various genetic disorders
linked to the above metabolic pathways and thiamine
deficiency syndromes (beriberi and Wernicke-Korsakoff
syndrome). Oral thiamine may also have a role in treat-
ing some of the pathophysiologic conditions associated
with diabetes, heart failure, and hypermetabolic states
[2-5].
The optimum dosing for these beneficial effects is
unknown. Rare side effects of thiamine have been attrib-
uted to allergic reactions. And although, ganglionic
blockade can occur at extremely high intravenous doses,
oral dosing of 3 g per day and higher have been used
for extended periods of time without deleterious effects
[6-8].
Free thiamine is taken-up by the body by a saturable
transport system in the proximal small intestine that
was thought to severely limit the amount of thiamine
t h a tc a nb ea b s o r b e db yas i n g l eo r a ld o s e[ 9 - 1 1 ] .F o r
this reason, alternate forms of thiamine (S-acyl thiamine
derivatives and lipid-soluble thiamine disulfide deriva-
tives), that are more absorbable by the body, had been
developed [12]. However, free thiamine may be taken-up
b yt h eb o d yb yb o t has a t u r a b l ea c t i v et r a n s p o r ts y s t e m
and a nonsaturable passive process. Thus high doses of
thiamine hydrochloride may be absorbable.
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thiamine at doses that are typically used and virtually no
data on high-dose oral thiamine. The purpose of this
study was to determine the pharmacokinetic profile of
oral thiamine hydrochloride between 100 mg and 1500
mg in healthy subjects.
Methods
Subjects
The Institutional Review Board at Baystate Medical Cen-
ter approved this study. All subjects provided written
informed consent prior to participation. Fourteen
healthy subjects consented to be in the study (2 dropped
out on the first study day). Screening procedures
included a medical history, physical exam, hematologic
profile, blood chemistries, pregnancy test, and urine ana-
lysis. Subjects were not taking any medications nor were
they taking any dietary or herbal supplements.
Study design and procedures
Subjects participated in a randomized, double-blind, sin-
gle-dose, 4-way crossover study with a minimum of 1
week elapsing between trials. The 4 treatment groups
were:
1. Placebo
2. 100 mg thiamine hydrochloride
3. 500 mg thiamine hydrochloride
4. 1500 mg thiamine hydrochloride
Subjects fasted overnight except for water. In the
morning they had a blood sample drawn followed by a
standardized breakfast. After 1 hour they were adminis-
tered the study medication. Additional blood specimens
were obtained immediately prior to the study medica-
t i o na n da t0 . 5 ,1 ,1 . 5 ,2 ,3 ,4 ,5 ,6 ,8 ,a n d1 0h o u r sa f t e r
taking the study medication. Subjects received a standar-
dized lunch after the 6-hour blood draw. All blood spe-
cimens were drawn in duplicate (for plasma and whole
blood assays) in 3 mL lavender-top vacutainers
® con-
taining K2EDTA. They were immediately placed in an
ice bath and protected from the light. One vacutainer
®
of each pair was centrifuged at 3000 RPM for 20 min at
4°C to separate the plasma. The plasma sample and
whole blood sample were then frozen at -70°C.
Study medication
Thiamine tablets each containing 100 mg of thiamine
hydrochloride were used (Amneal Pharmaceuticals). These
were placed intact into opaque capsules. Identical capsules
containing sucrose tablets were used as placebo such that
the same number of capsules were used for each trial.
Analysis of blood specimens
Quest Diagnostics analyzed all specimens for total
thiamine using HPLC [4]. At Quest Diagnostics,
plasma was deproteinized and then incubated with
acid phosphatase to convert thiamine phosphate esters
to free thiamine. The free thiamine was then oxidized
to thiochrome by the addition of alkaline potassium
ferricyanide. Depending on the age of the column and
the temperature of the room, thiochrome retention
time varied from 2.5 to 3.0 min. The mixture was
injected to a Supelco (Bellefonte, PA, USA) high-per-
formance liquid chromatographic column (7.5 cm
3 4.6
mm, particle size 3 mm) connected to a high-perfor-
mance liquid chromatographic system using a Hitachi
(Pleasant, CA, USA) pump, autosampler, and fluores-
cent detector (excitation wavelength 365 nm, emission
wavelength 440 nm). The mobile phase was 75 mmol/
L of potassium phosphate at pH 7.5 with 25% metha-
n o l .T h ef l o wr a t ew a ss e ta t1 . 0m L / m i n .T h r o u g h
this process, the thiochrome was then separated from
other interfering substances and then measured fluoro-
metrically. The amount of total thiamine in an
unknown sample is proportional to the amount of
thiochrome formed. The limit of quantification is 7
nmol/L. The assay range is 7 to 450 nmol/L. Samples
with values above this range were diluted. The coeffi-
cient of variation for both the plasma and whole blood
thiamine assays was calculated from the data collected
in this study.
Pharmacokinetic and statistical analysis
The thiamine levels were corrected by subtracting the
baseline value. The baseline value was calculated as the
average of the -1-hour and 0-hour values. Net systemic
exposure to thiamine in each subject in each trial was
quantitated using the area under the whole blood or
plasma concentration curve from time zero through 10
hours after dosage (AUC0-10 hr). This was calculated
using the cubic splines method. The overall effect of
treatment condition (thiamine dose) on AUC0-10 hr in
blood and plasma was tested using analysis of variance
(ANOVA) for repeated measures. This was followed by
the Student-Newman-Keuls procedure, nonparametric
form, for evaluating all pairwise comparisons of the
mean AUC0-10 hr values for the dosage groups. The
peak thiamine concentration (Cmax)a n dt h et i m et o
peak thiamine concentration (Tmax) were also calculated.
Finally, half-life (t1\2) values were calculated where the
terminal phase appeared log-linear.
The relative impact of active and passive absorption
were assessed by comparing the AUC0-10 hr vs dose for
0 mg to 100 mg, 100 mg to 500 mg, and 500 mg to
1500 mg doses using multilevel mixed-effects linear
regression. This was then repeated for Cmax vs dose.
The data from the placebo trials was used to calculate
the coefficient of variation for both the plasma and
whole blood assays using the logarithmic method. The
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ficient of variation for whole blood was 0.11.
Stata statistical software version 11 was used for all
calculations.
Results
Fourteen subjects consented to be in the study. Of
these, 2 dropped out because of poor venous access dur-
ing the 1
st trial and their data are not included in this
analysis. Table 1 lists the demographics of the subjects.
Table 2 shows the pharmacokinetic values for the whole
blood and plasma thiamine measures.
Figures 1 and 2 show whole blood and plasma thia-
mine concentrations vs time plots for each thiamine
dose. The overall effect of dose was significant (Plasma:
ANOVA p < 0.001; Whole Blood: ANOVA p <0 . 0 0 1 ) .
Additionally, the mean AUC0-10 hr for each dose was
also significantly different from the others (Student-
Newman-Keuls procedure, p < 0.05).
Figures 3 and 4 show semi-log plots of the terminal
phase of thiamine concentration vs time plots for each
thiamine dose for whole blood and plasma. The plots
suggest that the terminal phase of thiamine concentra-
tion vs time for the 1500 mg dose (whole blood) as well
as the 500 mg and 1500 mg doses (plasma) are log-lin-
ear. The half-life was calculated for these doses: 4.78 ±
2.02 hrs (1500 mg, whole blood), 3.92 ± 2.24 hrs (500
mg, plasma), and 2.97 ± 1.05 hrs (1500 mg, plasma).
Figures 5 and 6 show the AUC0-10 hr vs thiamine dose
plots for whole blood and plasma. Figures 7 and 8 show
the Cmax vs thiamine dose plots for whole blood and
plasma. These plots suggest that the slope is steepest
between 0 mg and 100 mg doses of thiamine. This was
then tested in separate multilevel mixed effects models
and the results are shown in Table 3. The steepest slope
is between 0 mg and 100 mg suggesting that while
active and passive transport probably occur at all doses,
active and transport is more dominant at lower thiamine
doses compared to higher thiamine doses. The lack of
reaching statistical significance comparing the 0 mg -
100 mg to the 500 mg - 1500 mg segment should be
interpreted cautiously because of the small sample size
of this study.
Discussion
The mechanism of how thiamine is absorbed has been
somewhat controversial. One group of researchers con-
cluded that thiamine is only absorbed by a saturable
active transport mechanism in the proximal small intes-
tine; however other researchers have shown that thia-
mine is also absorbed by a passive process [13]. Several
studies by Thomson demonstrated that a maximum
amount between 4.8 and 8.3 mg of thiamine could be
absorbed by a single oral dose of thiamine hydrochlor-
ide. In these studies, subjects were given a single dose
oral thiamine between 1 and 20 mg [9-11]. In another
study, Morrison, found that very little thiamine was
excreted in urine when doses above 2.5 mg were given
orally [14]. This saturable active transport mechanism
has been attributed to two carriers, thiamine transpor-
ter-1 and thiamine transporter-2.
Using a study design where thiamine was infused
directly into the lumen of the small intestine, Hoyumpa
demonstrated that thiamine was absorbed by an active
process at low concentrations (0.2 to 2.0 μM) and by a
Table 1 Demographics
Age (years) 29 (10)
Weight (kg) 87 (20)
Gender
Female 64%
Male 36%
Race
White 79%
Black 21%
Ethnicity
Hispanic 36%
Non-Hispanic 64%
Hemoglobin (g/dL) 15 (4)
Sodium (mmol/L) 139 (2)
Potassium (mmol/L) 4.1 (0.3)
Chloride (mmol/L) 102 (2)
Bicarbonate (mmol/L) 27 (2)
Glucose (mg/dL) 92 (9)
BUN (mg/dL) 13 (3)
Creatinine (mg/dL) 0.8 (0.2)
values are either mean (SD) or percentages
Table 2 Pharmacokinetic Values
PARAMETER THIAMINE DOSE
100 mg 500 mg 1500 mg
AUC0-10 hr (nmol/Liter × hours)
whole blood 214 ± 69 623 ± 178 2046 ± 1222
plasma 177 ± 62 612 ± 257 2059 ± 1415
Cmax (nmol/Liter)
whole blood 40 ± 11 95 ± 27 385 ± 188
plasma 39 ± 13 113 ± 42 397 ± 250
Tmax (hours)
whole blood 3.43 ± 1.69 4.14 ± 1.57 4.14 ± 0.90
plasma 3.14 ± 1.05 3.18 ± 0.98 4.27 ± 1.01
All values are presented as mean ± standard deviation. p < 0.05 for all
pairwise comparisons (plasma and whole blood values were analyzed
separately)
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Figure 1 Oral Thiamine Whole Blood Concentration vs Time Plot. The concentration of thiamine in plasma from 0 hour to 10 hours after
100 mg (♦), 500 mg (●) and 1500 mg (■) of oral thiamine. Error bars are standard deviations.
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Figure 2 Oral Thiamine Plasma Concentration vs Time Plot. The concentration of thiamine in whole blood from 0 hour to 10 hours after
100 mg (♦), 500 mg (●) and 1500 mg (■) of oral thiamine. Error bars are standard deviations.
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Figure 3 Semi-log Plot of the Terminal Phase of Oral Thiamine Whole Blood Concentration vs Time. The concentration of thiamine in
whole blood from 4 hour to 10 hours after 100 mg (♦), 500 mg (●) and 1500 mg (■) of oral thiamine.
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Figure 4 Semi-log Plot of the Terminal Phase of Oral Thiamine Plasma Concentration vs Time. The concentration of thiamine in plasma
from 4 hour to 10 hours after 100 mg (♦), 500 mg (●) and 1500 mg (■) of oral thiamine.
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Figure 5 Whole Blood 0 to 10 Hour AUC vs Thiamine Dose Plot. The mean area under the curve values for whole blood thiamine measures
from time 0 hour to time 10 hours vs thiamine dose after 0 mg, 100 mg, 500 mg and 1500 mg of oral thiamine. Error bars are 95% confidence
intervals.
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Figure 6 Plasma 0 to 10 Hour AUC vs Thiamine Dose Plot. The mean area under the curve values for plasma thiamine measures from time 0
hour to time 10 hours vs thiamine dose after 0 mg, 100 mg, 500 mg and 1500 mg of oral thiamine. Error bars are 95% confidence intervals.
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Figure 7 Whole Blood Cmax vs Thiamine Dose Plot. The mean maximum whole blood thiamine concentration between time 0 hour and
time 10 hours vs thiamine dose after 0 mg, 100 mg, 500 mg and 1500 mg of oral thiamine. Error bars are 95% confidence intervals.
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Figure 8 Plasma Cmax vs Thiamine Dose Plot. The mean maximum whole blood thiamine concentration between time 0 hour and time 10
hours vs thiamine dose after 0 mg, 100 mg, 500 mg and 1500 mg of oral thiamine. Error bars are 95% confidence intervals.
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Page 7 of 10passive process at higher concentrations (5.0 to 50.0
μM) [15-18]. This was also found in an in vitro study
[19]. Thomson found a linear relationship between urin-
ary excretion and oral dose of thiamine between 10 and
50 mg [20]. This is further supported by Weber who
gave a single dose of oral thiamine to 3 subjects (50,
100, or 200 mg) and found that the subject given the
largest oral dose also had the highest plasma thiamine
levels [21]. Although, the design of this study and its
small sample size limits any conclusions.
Studies to determine the optimal dosing of thiamine
for various conditions have not been performed and
dosing recommendations appear to be based on limited
data. Thiamine deficiency syndromes are typically initi-
ally treated with intravenous thiamine between 100 mg
once a day and 500 mg three times a day [22,23]. Oral
dosing of thiamine up to 100 mg/kg divided three times
a day have been reported to be required to treat chil-
dren with genetic abnormalities of pyruvate dehydrogen-
ase. Children with these abnormalities who were not
improved by taking thiamine, may have been treated
with an inadequate dosage [24]. In studies of Alzhei-
mer’s disease, subjects were treated with 1000 mg of
oral thiamine hydrochloride three times a day for 2 to
12 months without any reports of adverse effects
[7,25,26]. In a separate experiment, subjects were
titrated up to 8000 mg per day over a 1-year period.
The only side effects reported were nausea and indiges-
tion in 2 subjects when they reached 7000 and 7500 mg
per day [7]. There have been several clinical trials of
thiamine derivatives for a variety of disorders that used
doses between 300 and 900 mg per day in divided doses
for periods up to 3 months. No side effects were
reported in these studies [2,27-29].
Alternate forms of oral thiamine (S-acyl thiamine deri-
vatives and lipid-soluble thiamine disulfide derivatives)
have been developed because they have a much higher
bioavailability than thiamine hydrochloride [12].
Thiamine hydrochloride has been estimated to have a
bioavailability between 3.7% and 5.3% [21,30]. However,
it is not clear that these thiamine derivatives are needed.
First, tissue uptake is highly variable across different tis-
sues and different derivatives [12]. Second, oral thiamine
hydrochloride when given over a 1-week period produce
blood levels that approach those obtained by intramus-
cular and intravenous administration [31,32]. Finally, in
vitro studies that have compared thiamine to thiamine
derivatives have generally found them to have similar
effects [33-38]. In studies where a thiamine derivative
was thought to be superior to thiamine hydrochloride,
the difference could be completely explained by differ-
ences in bioavailability [39-41].
This study has demonstrated that the absorption
mechanism is not saturable up to 1500 mg. Our results
are consistent with a combination of passive and active
transport. The active transport plays a larger role in
thiamine absorption at lower doses compared to higher
doses. These results contradict the results found by
Thomson but is consistent with the animal studies
done by Hoyumpa. The constant difference between
plasma and whole blood thiamine levels is consistent
with a rapid equilibrium between red blood cells and
plasma.
This study was limited in that we did not measure tis-
sue levels of thiamine nor did we measure biological
effects of high dose oral thiamine hydrochloride. Addi-
tionally, while no side effects were reported, this study
was not designed to detect adverse events. Our calcula-
tion of the coefficient of variation has additional limita-
tions. It includes error related to the analytic method in
addition to error related to biologic variation as well as
all of the steps between obtaining the blood and its pre-
paration prior to analysis. A greater understanding of
the absorption process could have determined if we stu-
died a larger number of thiamine doses and followed
the subjects for a longer period of time.
Table 3 Comparison of Slopes for 0 to 10 Hour AUC vs Thiamine Dose
AUC0-10 hr Cmax
Segment Slope p-value* Slope p-value*
0 to 100 mg
whole blood 2.14 0.40
plasma 1.76 0.39
100 mg to 500 mg
whole blood 1.02 < 0.01 0.14 < 0.01
plasma 1.09 0.06 0.18 < 0.01
500 mg to 1500 mg
whole blood 1.42 0.06 0.29 0.03
plasma 1.45 0.40 0.29 0.08
*Compared to the 0 to 100 mg segment
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In conclusion, our study demonstrates that high blood
levels of thiamine can be achieved rapidly with oral thia-
mine hydrochloride. Thiamine is absorbed by both an
active and unsaturable passive transport mechanism up
to 1500 mg.
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